Free Trial
NASDAQ:MXCT

MaxCyte (MXCT) Stock Price, News & Analysis

MaxCyte logo
$1.38 -0.05 (-3.50%)
Closing price 04:00 PM Eastern
Extended Trading
$1.39 +0.01 (+1.01%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MaxCyte Stock (NASDAQ:MXCT)

Key Stats

Today's Range
$1.36
$1.50
50-Day Range
$1.38
$2.39
52-Week Range
$1.36
$5.20
Volume
1.40 million shs
Average Volume
587,734 shs
Market Capitalization
$147.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Moderate Buy

Company Overview

MaxCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

MXCT MarketRank™: 

MaxCyte scored higher than 48% of companies evaluated by MarketBeat, and ranked 573rd out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MaxCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    MaxCyte has only been the subject of 2 research reports in the past 90 days.

  • Read more about MaxCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for MaxCyte are expected to grow in the coming year, from ($0.42) to ($0.41) per share.

  • Price to Book Value per Share Ratio

    MaxCyte has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.56% of the float of MaxCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    MaxCyte has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in MaxCyte has recently increased by 1.16%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    MaxCyte does not currently pay a dividend.

  • Dividend Growth

    MaxCyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.56% of the float of MaxCyte has been sold short.
  • Short Interest Ratio / Days to Cover

    MaxCyte has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in MaxCyte has recently increased by 1.16%, indicating that investor sentiment is decreasing.
  • News Sentiment

    MaxCyte has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for MaxCyte this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for MXCT on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MaxCyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.30% of the stock of MaxCyte is held by insiders.

  • Percentage Held by Institutions

    68.81% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MaxCyte's insider trading history.
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

MXCT Stock News Headlines

MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript
MaxCyte (MXCT) Q2 Revenue Drops 18%
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
MaxCyte Inc (MXCT) Q2 2025 Earnings Report Preview: What To Expect
MaxCyte (MXCT) Projected to Post Earnings on Wednesday
MaxCyte Signs Platform License Agreement with Adicet Bio
See More Headlines

MXCT Stock Analysis - Frequently Asked Questions

MaxCyte's stock was trading at $4.16 at the beginning of the year. Since then, MXCT shares have decreased by 66.8% and is now trading at $1.38.

MaxCyte, Inc. (NASDAQ:MXCT) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.02. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $9.57 million. MaxCyte had a negative net margin of 125.22% and a negative trailing twelve-month return on equity of 22.12%.
Read the conference call transcript
.

MaxCyte (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at a price of $11.50-$13.50 per share.

Top institutional shareholders of MaxCyte include Geode Capital Management LLC (2.33%), Chevy Chase Trust Holdings LLC (1.62%), Rathbones Group PLC (0.22%) and Los Angeles Capital Management LLC (0.06%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, Stanley C Erck, John Joseph Johnston, Douglas J Swirsky, Richard Douglas, Maher Masoud, David I Sandoval, Ali Soleymannezhad and Thomas M Ross.
View institutional ownership trends
.

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MaxCyte investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
8/06/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Business Services
Current Symbol
NASDAQ:MXCT
CIK
1287098
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$6.00
Potential Upside/Downside
+407.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$41.06 million
Net Margins
-125.22%
Pretax Margin
-110.92%
Return on Equity
-21.70%
Return on Assets
-18.71%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.23
Quick Ratio
11.58

Sales & Book Value

Annual Sales
$37.68 million
Price / Sales
3.90
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.95 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
106,416,000
Free Float
102,904,000
Market Cap
$146.85 million
Optionable
Optionable
Beta
1.23

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:MXCT) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners